Welcome to our dedicated page for Ehave news (Ticker: EHVVF), a resource for investors and traders seeking the latest updates and insights on Ehave stock.
The Ehave Inc. (EHVVF) news feed on Stock Titan aggregates company communications and related updates that describe its evolution into an applied artificial intelligence platform operator. Recent press releases highlight Ehave’s acquisition of AIHeadHunter, an AI-powered recruitment platform designed to automate and streamline executive search and talent sourcing through advanced data analysis. These announcements provide insight into how Ehave is repositioning itself around data-driven technology assets and AI-enabled business models.
News linked to Ehave also frequently references its subsidiary AIBotics, Inc. (traded as AIBT), which is described as a developer and manager of AI- and robotics-enhanced technologies. AIBotics press releases cover topics such as the development and pilot deployment of the Phill Robot™ massage robot, the Milkyway smart refrigerator, and partnerships aimed at distributing service robots in markets like Israel and Jamaica. These items illustrate how Ehave’s subsidiary is working with AI, robotics, and agentic AI concepts to build products and platforms for wellness, service environments, and intelligent automation.
Investors and observers using this news page can review how Ehave describes its strategic realignment, including its focus on incubating scalable AI platforms and structuring transactions to support that shift. Coverage includes acquisition terms for AIHeadHunter, descriptions of the technology licensed for that platform, and statements about Ehave’s plans to fund and launch enterprise pilots. For AIBotics, the news flow includes product development milestones, collaboration agreements for UI/UX and operating platforms, and early commercialization efforts such as pilot programs in fitness and wellness facilities.
By following the EHVVF news page, readers can see how Ehave communicates its progress on AIHeadHunter, its relationship with AIBotics, and its broader approach to applied AI and robotics. The articles provide context on the company’s stated objectives, the markets it is targeting through its platforms, and the partnerships it reports as part of its growth plans.
Ehave, Inc. (OTC Pink: EHVVF) announced on September 30, 2021, that the Psychedelic Stock Review has initiated coverage of the company. Ehave is set to launch a range of digital tools aimed at enhancing the effectiveness of Psychedelic treatments. The company previously sold its Clinical Software Platform for $3.2 million and is transitioning to provide patient reporting services in the Psychedelic sector. Key upcoming products include KetaDash, MegaTeam, and the Ehave Health Records Dashboard, all designed to improve patient monitoring and data collection in the growing market for Psychedelic therapies.
Ehave (OTC Pink: EHVVF), a provider of digital therapeutics for the psychedelic and mental health sectors, announced its inclusion in the 2021 Psychedelic Investor Guide. This guide features leading companies in the emerging psychedelics medicine industry, showcasing Ehave's strategy of integrating digital therapeutics with psychedelic medicine. President Ben Kaplan emphasized that this recognition boosts investor awareness and highlights the company's significant initiatives. The guide aims to familiarize investors with key companies, further validating the potential for success in the psychedelics sector.
Ehave, Inc. (OTC Pink: EHVVF) announced the addition of Dr. Rahul Dixit to its Medical Advisory Board. Dr. Dixit, a Gastroenterology Specialist with over 17 years in the medical field, will advise on human trials for cognitive and psychedelic opportunities and mental health analytical platforms. His expertise in gastrointestinal ailments, particularly those linked to mental health, aligns with Ehave's focus on digital therapeutics for brain disorders. CEO Ben Kaplan expressed confidence in Dr. Dixit's valuable contributions as the company expands its operations.
Ehave, Inc. (EHVVF) announced the upcoming launch of its Covid Passport, aimed at helping small businesses verify Covid-19 vaccinations. This tool will simplify vaccination tracking for employers and provide individuals a secure method to store their vaccination records. The Covid Passport will be free for users, with enterprise pricing to be disclosed later. Additional products, including KetaDash, MegaTeam, and others, are also progressing towards release. CEO Ben Kaplan emphasized the Covid Passport's role in enhancing workplace safety amidst the pandemic.
Ehave, Inc. (OTC Pink: EHVVF) announced the filing of a Form 6-K with the SEC, revealing a Letter of Intent (LOI) to acquire Moksha Digital Software. This strategic move is projected to significantly enhance revenues, escalating from $10.19 million in the first year to approximately $150.42 million by year five. The Form 6-K also outlines fund utilization and a business plan over five years. The full filing can be accessed at the SEC's website.
Ehave, Inc. (EHVVF) announced a Letter of Intent to acquire Moksha Digital Software Pvt. Ltd., a healthcare software provider known for its FDA-cleared CuriePACS and CurieRIS solutions. The acquisition aims to enhance Ehave’s digital therapeutics portfolio and leverage Moksha's established sales channels to facilitate growth. Moksha Digital has a proven track record with expertise derived from founders with extensive backgrounds in leading companies. This strategic move is expected to expand Ehave's reach in medical imaging, particularly in the psychedelic and clinical trial sectors.
Ehave, Inc. (OTC Pink: EHVVF) has disclosed through a Form 6-K filing with the SEC that it entered into a Research Project Agreement with The University of Melbourne on July 2, 2021. This agreement aims to gather data and biomarkers for targeting Hallucinogen Persisting Perception Disorder (HPPD). Ehave focuses on digital therapeutics for brain disorders and offers platforms like the Ehave Telemetry Portal and Ehave Infinity Portal, designed to enhance patient care through data-driven insights.
Ehave, Inc. (EHVVF) announced the licensing of advanced AI technology from Vastmindz to enhance its Ehave Dashboard and Ehave Medical App. This proprietary computer vision technology enables the apps to assess physiological conditions like heart rate and oxygen saturation by analyzing facial skin light absorption. The integration aims to improve remote healthcare by providing seamless data aggregation and enhancing interactions between healthcare providers and patients. CEO Ben Kaplan highlighted the technology's role in democratizing healthcare and improving treatment outcomes.
Ehave, Inc. (EHVVF) announces a partnership with a globally recognized university to investigate Hallucinogen Persisting Perception Disorder (HPPD). The study, lasting 12 months, aims to gather data and bio-markers to create screening products and a revenue model. It consists of three stages: identifying visual task assessments, expanding the study to a larger sample, and developing a web-based test platform. CEO Ben Kaplan emphasized the importance of this initiative for understanding HPPD and enhancing treatment safety.
Ehave, Inc. (EHVVF) announced plans for large-scale studies on hallucinogen-persisting perception disorder (HPPD), which affects a minority of psychedelic users with lingering visual disturbances. CEO Ben Kaplan emphasized the intention to explore genetic predispositions and develop visual processing tests within their therapeutic app. The company aims to be an industry leader in minimizing treatment side effects. This research could represent the largest patient study of HPPD to date, with potential implications for broader psychedelic therapy acceptance.